Allergan (AGN) Dips as FDA Approves Sientra Silimed-Brand Implants
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/14/2026
- Nasdaq ends down as chipmakers fall and bank earnings roll in
- Oil prices settle mixed, focus on US-Russia diesel deal, Saudi Yemen attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Tweet
Share
E-mailGet Alerts AGN Hot Sheet
Join SI Premium – FREE
Allergan, Inc. (NYSE: AGN) is ticking lower today following a release from competitor Sientra that it has received FDA approval of its portfolio of Silimed-brand silicone breast implants.
Shares are down 0.3 percent on the session Friday after being up as much as 0.8 percent on the session.
Shares are down 0.3 percent on the session Friday after being up as much as 0.8 percent on the session.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biomea Fusion reports Phase 1 weight loss data for oral GLP-1 drug
- Entera Bio shares Phase 2 EB613 bone density data at ASBMR meeting
- J&J's Tremfya shows fistula remission in Crohn's subgroups
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
